Changes in survival in people with IPF in England 2010–2020

<bold>Background:</bold> Despite trial evidence of benefit, it is unknown whether survival has improved in the UK IPF population since the introduction of antifibrotics in the mid-2010s. <bold>Methods:</bold> Using linked Clinical Practice Research Datalink Aurum & Hospital Episode Statistics data, we calculated median survival times for patients diagnosed with IPF in 2010 and each year thereafter until 2018. For 2010–2020, we estimated age-and sex-adjusted hazard ratios for death (relative to 2010) and age-and sex-standardized all-cause mortality rates. We repeated our analyses using four differently-defined cohorts to explore whether survival and mortality trends were sensitive to coding choices for IPF case finding.¹ <bold>Results:</bold> In our study population (n=46,527) there was no significant difference in median survival (years) between those newly-diagnosed in 2010 and 2018 [Aurum narrow cohort=4.6 (95%CI,3.7–5.4) vs 3.7(3.4–4.3); Aurum broad cohort=3.7(3.4–4.0) vs 4.2(3.8–4.4)]. Age-and sex-adjusted Cox models with all-cause mortality as the outcome also provided no evidence of improved survival but age-and sex-standardized mortality rates increased over the study period (Fig.) These trends were independent of IPF case definitions. <bold>Conclusion:</bold> Between 2010 and 2020, survival time among IPF patients remained unchanged while the mortality rate increased. Longer follow-up time is needed to fully assess the impact of antifibrotics in this population. ¹ Morgan et al. BMC Pulm Med. 2023;23:256. <fig><object-id>erj;64/suppl_68/PA5146/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>